
Please try another search
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in Emeryville, California.
Name | Age | Since | Title |
---|---|---|---|
Jacob M. Chacko | 43 | 2019 | Independent Director |
Ronal Crystal | - | 2023 | Member of Scientific Advisory Board |
Shawn Cline Tomasello | 65 | 2020 | Independent Director |
Susannah Gray | 63 | 2020 | Independent Director |
Charles P. Theuer | 60 | 2015 | Independent Director |
Nancy B. Miller-Rich | 65 | 2020 | Independent Director |
Arshad M. Khanani | - | 2024 | Chair of Ophthalmology Advisory Board |
David H. Kirn | 62 | 2013 | Co-Founder, CEO & Director |
John F. Milligan | 64 | 2020 | Executive Chairman |
Noriyuki Kasahara | 62 | 2022 | Member of Scientific Advisory Board |
Paul J. Utz | - | 2023 | Member of Scientific Advisory Board |
Wenchao Song | - | 2024 | Member of Scientific Advisory Board |
Anat Loewenstein | - | 2024 | Member of Ophthalmology Advisory Board |
Frank G. Holz | - | 2024 | Member of Ophthalmology Advisory Board |
Dante Pieramici | - | 2024 | Member of Ophthalmology Advisory Board |
Douglas Hanahan | - | - | Member of the Scientific Advisory Board |
Richard B. Moss | - | 2023 | Member of Scientific Advisory Board |
Amy Rosenberg | - | 2023 | Member of Scientific Advisory Board |
Amit Gaggar | - | 2023 | Member of Scientific Advisory Board |
David S. Boyer | - | 2024 | Member of Ophthalmology Advisory Board |
Napoleone Ferrara | 68 | 2024 | Member of Scientific Advisory Board |
Ronald G. Crystal | - | - | Member of the Scientific Advisory Board |
John P. Atkinson | - | 2024 | Member of Scientific Advisory Board |
Patricio G. Schlottmann | - | 2024 | Member of Ophthalmology Advisory Board |
Gemmy Cheung | - | 2024 | Member of Ophthalmology Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review